The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia.

نویسندگان

  • Kathelijn Fischer
  • Johanna G van der Bom
  • Eveline P Mauser-Bunschoten
  • Goris Roosendaal
  • Robert Prejs
  • Piet de Kleijn
  • Diederick E Grobbee
  • Marijke van den Berg
چکیده

To prevent hemophilic arthropathy, prophylactic treatment of children with severe hemophilia should be started before joint damage has occurred. However, treatment is expensive, and the burden of regular venipunctures in young children is high. With the aim of providing information on starting prophylaxis on the basis of individual patient characteristics, the effect of postponing prophylaxis on long-term arthropathy was studied in a cohort of 76 patients with severe hemophilia born between 1965 and 1985. The median age at first joint bleed was 2.2 years (range, 0.2-5.8). Prophylaxis was started at a median age of 6 years (interquartile range [IQR], 4-9), and the median annual clotting factor use on prophylaxis was 1750 IU/kg/y (31 IU/kg/wk). Hemophilic arthropathy was measured by the Pettersson score (maximum, 78 points). At a median age of 19 years, the median Pettersson score was 7 points (IQR, 0-17). After 2 decades of follow-up, the Pettersson score was 8% higher (95% confidence interval, 1%-16%) for every year prophylaxis was postponed after the first joint bleed. This effect was independent of age at Pettersson score, age at first joint bleed, and prophylactic dose used. In conclusion, most patients have their first joint bleed after the age of 2 years. Patients who start prophylaxis soon after the first joint bleed show little arthropathy in adulthood. The longer the start of prophylaxis is postponed after the first joint bleed, the higher the risk of developing arthropathy.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

The Effects of Prophylactic Treatment of the Central Nervous System on the Intellectual Functioning Of Children with Acute Lymphocytic Leukemia

Abstract Objective The great majority of patients with childhood leukemia become long-term survivors. They treated with chemotherapy and prophylactic central nervous system (CNS) irradiation. The aim of this cross-sectional study was to evaluate effect of the long-term toxicity in ALL survivors, and possible effects of this treatment on their intellectual in compare with their sibling. Mater...

متن کامل

Recent Advances in Hemophilia Gene Therapy

Heterogeneous loss of function mutations at F8 and F9 genes causes X-linked recessive bleeding disorders, hemophilia A (HA) and hemophilia B (HB), respectively. HA is clinically indistinguishable from HB and accounts for more than 80% of hemophilia cases; the former affects 1/5000 and the latter 1/25000 male births worldwide. In Iran, it is estimated that around 4300 HA and 900 HB patients are ...

متن کامل

A modeling approach to evaluate long-term outcome of prophylactic and on demand treatment strategies for severe hemophilia A.

BACKGROUND Severe hemophilia requires life-long treatment with expensive clotting factor concentrates; studies comparing effects of different therapeutic strategies over decades are very difficult to perform. A simulation model was developed to evaluate the long-term outcome of on demand, prophylactic and mixed treatment strategies for patients with severe hemophilia A. DESIGN AND METHODS A c...

متن کامل

The effect of on demand and prophylactic therapeutic methods on quality of life among hemophilic children

Background: Treating a chronic disease such as hemophilia is to improve the symptoms and quality of life (QOL) of the patients. This study aimed to study the quality of life among hemophilic children and compare the quality of life between patients receiving prophylactic or on demand treatments. Materials and Methods: In this descriptive-comparative study, we enrolled 60 patients from three ...

متن کامل

Rituximab for Treatment of Hemophilia A with High-Responder Inhibitors

Background: The development of inhibitors is a complication factor replacement therapy in hereditary factor VIII deficiency. Several management options are available for the treatment of inhibitor. Rituximab, a monoclonal antibody against CD20, reduces inhibitor level in rare bleeding disorders. The aim of this study was to evaluate the effectiveness of rituximab in lowering or eliminating the ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Blood

دوره 99 7  شماره 

صفحات  -

تاریخ انتشار 2002